Study Summary
This trial is testing a new cancer drug, APG-2575, to see if it is safe and effective in patients with multiple myeloma who have relapsed or are refractory to other treatments. The study will start with two arms, both of which are independent.
- Multiple Myeloma
- Amyloidosis
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: 28 days
Trial Safety
Safety Progress
Trial Design
4 Treatment Groups
APG-2575 +Pd or LD
1 of 4
APG-2575+LD
1 of 4
APG2575 +Pd or LD
1 of 4
APG2575+LD
1 of 4
Experimental Treatment
108 Total Participants · 4 Treatment Groups
Primary Treatment: APG2575 + DRd · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 99 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Could you provide a synopsis of previous experiments involving APG2575 + DRd?
"At present, there are 757 active studies for APG2575 + DRd with 169 trials in the Phase 3 stage. While Joliet, Illinois is one of many locations conducting these trials, 26277 sites around the world have been enlisted to participate." - Anonymous Online Contributor
What is the scope of individuals receiving treatment in this trial?
"To reach the target of 108 qualified participants, Ascentage Pharma Group Inc., will be running this trial at multiple sites such as Mayo Clinic in Jacksonville and Cleveland Clinic Hosptials in Ohio." - Anonymous Online Contributor
Is this study currently open to new participants?
"Affirmative. According to clinicaltrials.gov, this trial is actively seeking suitable candidates and was first published on December 23rd 2021. The most recent edit was made on February 28th 2022, with 108 volunteers needed from 3 different locations." - Anonymous Online Contributor
Is it possible for me to participate in this clinical trial?
"Applicants to this trial need to have a diagnosis of amyloidosis and be between 18 and 99 years old. The capacity for the study is 108 participants." - Anonymous Online Contributor
Does this clinical trial allow adults over the age of thirty to participate?
"This medical trial requires applicants to be between 18 and 99 years of age. It should also be noted that there are 124 clinical trials designed for those under the legal threshold, as well as 1560 studies catered towards elderly individuals." - Anonymous Online Contributor
What clinical conditions does the combination of APG2575 and DRd typically address?
"APG2575 + DRd is frequently prescribed for ophthalmia, sympathetic and can be used to treat a range of issues such as at least two previous systemic chemotherapy regimens, branch retinal vein occlusion, macular edema." - Anonymous Online Contributor